Results 61 to 70 of about 850,964 (168)
Psilocybin-Assisted Psychotherapy: Treating Depression and Anxiety with Mushrooms
, 2020 Depression and anxiety are debilitating mental health conditions that affect a large portion of the United States. Current pharmacological treatments for these disorders require daily administration, are associated with a number of side effects, and can be ineffective for some. Emerging evidence in novel treatment options may necessitate a shift toward
openaire +3 more sources
Scientific ReportsSeveral phase II studies have demonstrated that psilocybin-assisted therapy shows therapeutic potential across a spectrum of neuropsychiatric conditions, including major depressive disorder (MDD).
Jordan Sloshower +7 more
doaj +1 more source
With great power comes great responsibility: Promise and caution in the new psychedelic renaissance
Brain DisordersClinicians and researchers are showing increased interest in psychedelic-assisted therapy for patients who don't show improvement from using conventional antidepressants.
Matthew Halma, Rakeem Levy, Joseph Varon
doaj +1 more source
MedicinaBackground and Objectives: Substance use disorders (SUDs) affect millions worldwide. Despite increasing drug use, treatment options remain limited.
Lavinia Hogea +7 more
doaj +1 more source
Registered Clinical Trials of Ayahuasca and DMT: A Scoping Review
Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 94-108, July 2026.Interest in ayahuasca and its main component, N,N‐Dimethyltryptamine (DMT), has currently moved from historical and experimental use into modern clinical development. Yet, current evidence is fragmented, and systematic mapping of trial methods and design choices remains limited.
Tijana Stojanović +4 more
wiley +1 more source
Harms and benefits associated with psychoactive drugs: findings of an international survey of active drug users. [PDF]
, 2013 There have been several recent efforts in the UK and the Netherlands to describe the harms of psychoactive substances based on ratings of either experts or drug users.
Noronha, LA +4 more
core
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Frontiers in Pharmacology, 2018 Mental disorders are rising while development of novel psychiatric medications is declining. This stall in innovation has also been linked with intense debates on the current diagnostics and explanations for mental disorders, together constituting a ...
Eduardo Ekman Schenberg
doaj +1 more source
British Journal of Pharmacology, Volume 183, Issue 14, Page 4048-4057, July 2026.Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic ...
David J Nutt +3 more
wiley +1 more source
What is the Oregon Psilocybin Services Act?. American Sign Language
, 2022 An overview of the Oregon Psilcoybin Services Act (ORS 475A).This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.
core
Psilocybin as a novel treatment for chronic pain
British Journal of Pharmacology, Volume 183, Issue 14, Page 3992-4005, July 2026.Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey +3 more
wiley +1 more source